Researchers identified a peptide that selectively blocks pain signaling in sensory neurons and packaged it into a viral-based gene therapy in a step towards treating chronic pain without the risk for addiction.
On a quest to bring new a new hemophilia gene therapy to the clinic, one research team leapt over hurdle after hurdle to produce enough viral therapeutics to treat a large number of patients.
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.